X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology.
Lead Product(s): Typhoid Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Vaxxas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2023
Details:
Under the partnership, SK bioscience will explore potential future collaborations with Novavax such as utilizing the Novavax's adjuvant, Matrix-M for advancing protein-based vaccines inclding, Nuvaxovid (NVX-CoV2373) to prevent COVID-19.
Lead Product(s): NVX-CoV2373,Matrix-m1
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 08, 2023
Details:
GBP410 (21-Valent pneumococcal conjugate vaccine) vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae, which causes pneumococcal diseases such as pneumonia and invasive pneumococcal disease.
Lead Product(s): 21-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: GBP410
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-based influenza vaccine.
Lead Product(s): Quadrivalent Cell Culture-based Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Doherty Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 27, 2023
Details:
Sky Zoster vaccine consists live attenuated varicella virus which is administered subcutaneously for the prevention of herpes zoster in adults 50 years of age or older.
Lead Product(s): Live Attenuated Varicella Virus
Therapeutic Area: Infections and Infectious Diseases Product Name: Sky Zoster
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Under the agreement, SK bioscience will receive R&D expenses from CEPI. Initial funding will be made available to support phase 1/2 clinical trials of two mRNA vaccine platform projects.
Lead Product(s): mRNA-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2022
Details:
Nuvaxovid (also known as NVX-CoV2373) achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.
Lead Product(s): NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Novavax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
Under the agreement, SK bioscience, for the manufacturing and supply of a version of the Novavax COVID-19 vaccine (NVX-CoV2373) containing Omicron variant and for the manufacture of the vaccine in prefilled syringes.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration July 19, 2022
Details:
Protein-based SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 ‘GBP510’ with GSK pandemic adjuvant demonstrates superior neutralising titres compared to a control vaccine and clinically favourable safety profile.
Lead Product(s): GBP510
Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovione
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Nuvaxovid (NVX-CoV2373), a first protein-based COVID-19 vaccine inhibit SARS-CoV-2 protein, granted approval in South Korea in collaboration with SK bioscience, where the biologics license application was submitted to the MFDS in November.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Nuvaxovid
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Novavax
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
